
Sight Sciences (SGHT) Stock Forecast & Price Target
Sight Sciences (SGHT) Analyst Ratings
Bulls say
Sight Sciences Inc. has demonstrated a robust financial position with a gross margin of 86.8%, reflecting a year-over-year increase of 160 basis points and outperforming consensus estimates. Additionally, the company's expansion in ordering facilities, rising to 1,138, indicates a positive trajectory in operational growth, supported by anticipated gains in the minimally invasive glaucoma surgery (MIGS) market and accelerated adoption of the TearCare System. Furthermore, the forecasted revenue for 4Q24 of $18.9–19.1 million, along with the potential for profitability and sustained growth in the Surgical Glaucoma segment, presents a favorable outlook for the company’s future financial performance.
Bears say
Sight Sciences Inc. has exhibited disappointing financial performance, particularly within its Dry Eye segment, which reported revenue of $0.3 million, missing the consensus estimate of $0.4 million, despite an 81% year-over-year increase. The company’s overall revenue outlook for 1Q25 suggests a significant contraction, projected to decline by low- to mid-double digits year-over-year, further exacerbated by the negative impact of recently implemented Local Coverage Determinations (LCDs) on the OMNI Surgical System's utilization. Furthermore, the downward revisions of GAAP EPS estimates for 2025 and 2026—reducing forecasts to ($1.21) and ($1.03) respectively—underscore the anticipated challenges in revenue growth due to reimbursement headwinds.
This aggregate rating is based on analysts' research of Sight Sciences and is not a guaranteed prediction by Public.com or investment advice.
Sight Sciences (SGHT) Analyst Forecast & Price Prediction
Start investing in Sight Sciences (SGHT)
Order type
Buy in
Order amount
Est. shares
0 shares